IPA ImmunoPrecise Antibodies Ltd

---

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2023.

Commission File Number: 001-39530

ImmunoPrecise Antibodies Ltd.
(Exact Name of Registrant as Specified in Charter)

3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  □  Form 40-F ⊠

INCORPORATION BY REFERENCE

Exhibit 99.1 of this Form 6-K is incorporated by reference into the Registrant's Registration Statement on Form F-3 (File No. 333-273197) and Registration Statement on Form S-8 (File No. 333-256730).

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		IMMUNOPRECISE ANTIBODIES LTD.
Date:	November 16, 2023	By:	/s/ Kristin Taylor
		Name:	Kristin Taylor
		Title:	Chief Financial Officer

---

EXHIBIT INDEX

99.1	Report of Voting Results dated November 16, 2023

---

---

Report of Voting Results

Submitted Pursuant to

Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations

In accordance with Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, this report describes the matters voted upon and the outcome of the votes at the annual general meeting of shareholders of ImmunoPrecise Antibodies Ltd. (the "Corporation") held on November 9, 2023, via live webcast (the "Meeting"). Each of the matters is described in greater detail in the Corporation's management information circular dated October 16, 2023 (the "Circular").

(a) The number of directors was set at five. The following are the voting results on this matter:

(b) In the Circular, management of the Corporation proposed five nominees for election as directors of the Corporation for the ensuing year or until their successors are duly elected or appointed. All five nominees were elected. The following are the voting results on this matter:

(c) Grant Thornton LLP was reappointed as the Corporation's auditors and the directors were authorized to fix the remuneration to be paid to the auditors. The following are the voting results on this matter:

Dated this 16^th day of November 2023.

	IMMUNOPRECISE ANTIBODIES LTD.
	By:	(signed) Kristin Taylor
		Name: Kristin Taylor
		Title: Chief Financial Officer

---

---